Investments
130Portfolio Exits
32Funds
9About RiverVest Venture Partners
RiverVest Venture Partners focuses exclusively on life sciences, in particular in the medical device and biopharmaceutical industries. RiverVest also invests in select later-stage life science companies to diversify risk and maximize portfolio returns. Since its inception in September 2000, RiverVest has raised 2 investment funds with total committed capital of $164 million, and supported more than 20 life science companies.
RiverVest Venture Partners Headquarter Location
101 South Hanley Road Suite 1850
St. Louis, Missouri, 63105,
United States
314-726-6700
Latest RiverVest Venture Partners News
Feb 7, 2022
Biolinq Raises $100M and Unveils Micro-Sensing Tech Money will support development of the world’s smallest microarray of continuous glucose monitoring sensors. MPO Staff02.07.22 Investors have provided Biolinq Incorporated with $100 million to further develop its wearable glucose monitoring sensor. RiverVest Venture Partners led the financing round. “We now have an opportunity to expand the sensing category and deliver a new generation of sensing capabilities that can reach millions of lives in the diabetes community and beyond,” said Rich Yang, Biolinq’s CEO. “We’re grateful to RiverVest and our Biolinq co-founders, Jared Tangney, Ph.D., and Joshua Windmiller, Ph.D., for supporting and leading this important mission.” Biolinq’s approach in defining a new, personalized user experience includes needle-free sensor application, multiplexed sensing capabilities, and immediate biosensor feedback with a novel user interface on its compact wearable patch designed to simplify diabetes management and future consumer health and wellness applications. Early feasibility studies have demonstrated the capability of Biolinq’s microarray patch to track glucose levels continuously for up to seven days in people with diabetes. Biolinq's micro-array of biosensors measure interstitial fluid glucose levels just under the surface of the skin; the company leveraged innovation from the semiconductor industry to miniaturize electrochemical sensors designed for precision manufacturing and significant scale. Biolinq’s wearable patch is comprised of several independent, miniature biosensors (about 25 times smaller than conventional glucose sensors) that enable redundant measurements of target analytes, an important foundation for sensor reliability and consistent real-time performance. “We are pleased to be catalyzing this next stage of development for Biolinq’s novel biosensing applications,” said Nancy Hong, Ph.D., managing director at RiverVest Venture Partners. “Biolinq is a genuine game-changer—with a product platform designed to make continuous sensing simple and more accessible. The investment very much aligns with our goals to address unmet medical needs and support amazing entrepreneurs through science, strategy and innovation.” The $100 million in private capital raised includes contributions from T&W Medical, AXA IM Alts, Global Health Investment Corporation, Ascensia Diabetes Care, Longevity Vision Fund, Falcon Edge Capital, Aphelion Capital, M Ventures, Hikma Ventures, Senvest, The Broe Group, Taisho Pharmaceutical, Cirrus Logic, EOFlow, Able Partners, and the JDRF T1D Fund. “We are proud to invest in Biolinq’s bio-wearable multi-analyte platform that addresses major public health issues worldwide, starting with diabetes,” said Zina Affas Besse, Ph.D., managing partner, advising AXA IM Alts and Global Health Investment Corporation. “We look forward to supporting the company through the upcoming key clinical, regulatory, manufacturing and commercialization milestones, delivering global tangible impact alongside the potential for attractive financial returns.”
RiverVest Venture Partners Investments
130 Investments
RiverVest Venture Partners has made 130 investments. Their latest investment was in Bonum Therapeutics as part of their Series B on December 12, 2021.
RiverVest Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/22/2021 | Series B | Bonum Therapeutics | $1.19M | Yes | 1 | |
12/22/2021 | Series B | Good Therapeutics | $8M | No | 4 | |
11/23/2021 | Convertible Note - II | VentureMed Group | No | 2 | ||
10/15/2021 | Series B - II | |||||
9/15/2021 | Series B |
Date | 12/22/2021 | 12/22/2021 | 11/23/2021 | 10/15/2021 | 9/15/2021 |
---|---|---|---|---|---|
Round | Series B | Series B | Convertible Note - II | Series B - II | Series B |
Company | Bonum Therapeutics | Good Therapeutics | VentureMed Group | ||
Amount | $1.19M | $8M | |||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 1 | 4 | 2 |
RiverVest Venture Partners Portfolio Exits
32 Portfolio Exits
RiverVest Venture Partners has 32 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
10/22/2021 | IPO | 10 | |||
4/28/2021 | Acquired | 8 | |||
4/9/2021 | IPO | 2 | |||
Date | 10/22/2021 | 4/28/2021 | 4/9/2021 | ||
---|---|---|---|---|---|
Exit | IPO | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 10 | 8 | 2 |
RiverVest Venture Partners Fund History
9 Fund Histories
RiverVest Venture Partners has 9 funds, including RiverVest Venture Fund V.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
3/23/2021 | RiverVest Venture Fund V | $275M | 3 | ||
12/18/2018 | RiverVest Venture Fund IV | ||||
12/13/2016 | Archer Seed Fund | ||||
11/18/2016 | 3x5 RiverVest Fund II | ||||
5/5/2015 | RiverVest Venture Fund III |
Closing Date | 3/23/2021 | 12/18/2018 | 12/13/2016 | 11/18/2016 | 5/5/2015 |
---|---|---|---|---|---|
Fund | RiverVest Venture Fund V | RiverVest Venture Fund IV | Archer Seed Fund | 3x5 RiverVest Fund II | RiverVest Venture Fund III |
Fund Type | |||||
Status | |||||
Amount | $275M | ||||
Sources | 3 |
RiverVest Venture Partners Team
12 Team Members
RiverVest Venture Partners has 12 team members, including current Founder, Managing Director, Thomas C. Melzer.
Name | Work History | Title | Status |
---|---|---|---|
Thomas C. Melzer | Founder, Managing Director | Current | |
Jay W. Schmelter | Crescendo Ventures, Piper Sandler, Medtronic, and General Mills | Founder, Managing Director | Current |
Nancy J. Hutson | Senior Vice President | Current | |
Marilyn Slavich | Controller | Current | |
Gordon Foulkes | Managing Director | Current |
Name | Thomas C. Melzer | Jay W. Schmelter | Nancy J. Hutson | Marilyn Slavich | Gordon Foulkes |
---|---|---|---|---|---|
Work History | Crescendo Ventures, Piper Sandler, Medtronic, and General Mills | ||||
Title | Founder, Managing Director | Founder, Managing Director | Senior Vice President | Controller | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.